Foradil® Certihaler™
Partner: Novartis
Designed to ensure dose consistency
The Foradil® Certihaler™ is the multi-dose dry powder inhaler version of Novartis’ long-acting beta-2-agonist Foradil® (formoterol fumarate). SkyePharma developed both the multi-dose dry powder inhaler device (known as the SkyeHaler™) together with the formulation technologies designed to ensure dose consistency when the product is stored in a range of storage conditions.
In December 2006 the FDA approved a modified Foradil® Certihaler™ for the treatment of asthma in the USA. The original design of the device Foradil® Certihaler™ is approved in a number of countries outside of the USA.
For further information on Foradil® Certihaler™ and potential other applications of the SkyeHaler™ device, please contact SkyePharma.
Copyright 2008, SkyePharma. All Rights Reserved.
SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom
